CARLENE DEL CASTILLO: Open Payments
NPI 1699535971 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,511 in 71 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $175 · 2025 $1,511
Food & beverage: $1,511
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $376 |
| Lilly USA, LLC | 18 | $351 |
| PFIZER INC. | 13 | $245 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $153 |
| GlaxoSmithKline, LLC. | 7 | $136 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $72 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Astellas Pharma US Inc | 2 | $36 |
| Exact Sciences Corporation | 1 | $25 |
| AstraZeneca Pharmaceuticals LP | 1 | $23 |
Products named: Wegovy, MOUNJARO, CAPLYTA, TRELEGY ELLIPTA, JARDIANCE, ELIQUIS, PREVNAR 20, Ozempic.
Industry payments across IL — which companies pay providers there.
